CA2066945C - Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam - Google Patents

Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam Download PDF

Info

Publication number: CA2066945C
Authority: CA; Canada
Prior art keywords: composition according; foam; active ingredient; salt; composition
Prior art date: 1991-04-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2066945

Other languages

English (en)

French (fr)

Other versions

CA2066945A1 (en

Inventor

Stefano Poli

Germano Coppi

Cesare Busetti

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Polichem SA

Original Assignee

Polichem SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-24

Filing date

1992-04-23

Publication date

2004-06-22

1991-04-24 Priority claimed from ITMI911149A external-priority patent/IT1247529B/it

1992-04-23 Application filed by Polichem SA filed Critical Polichem SA

1992-10-25 Publication of CA2066945A1 publication Critical patent/CA2066945A1/en

2004-06-22 Application granted granted Critical

2004-06-22 Publication of CA2066945C publication Critical patent/CA2066945C/en

2012-04-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000006260 foam Substances 0.000 title claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
239000000203 mixture Substances 0.000 claims abstract description 41
239000004480 active ingredient Substances 0.000 claims abstract description 22
239000007788 liquid Substances 0.000 claims abstract description 8
239000004094 surface-active agent Substances 0.000 claims abstract description 8
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
239000002253 acid Substances 0.000 claims abstract description 3
239000002671 adjuvant Substances 0.000 claims abstract description 3
230000007935 neutral effect Effects 0.000 claims abstract description 3
NKDJNEGDJVXHKM-UHFFFAOYSA-N n,2-dimethyl-4,5,6,7-tetrahydroindazol-3-amine Chemical group C1CCCC2=NN(C)C(NC)=C21 NKDJNEGDJVXHKM-UHFFFAOYSA-N 0.000 claims description 10
229950006500 tetridamine Drugs 0.000 claims description 10
MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical group NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 claims description 9
229960004375 ciclopirox olamine Drugs 0.000 claims description 9
UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 claims description 8
229960001163 pidotimod Drugs 0.000 claims description 8
230000003110 anti-inflammatory effect Effects 0.000 claims description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
239000003380 propellant Substances 0.000 claims description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
OMDMTHRBGUBUCO-IUCAKERBSA-N (1s,5s)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol Chemical compound CC1=CC[C@H](C(C)(C)O)C[C@@H]1O OMDMTHRBGUBUCO-IUCAKERBSA-N 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
239000011782 vitamin Substances 0.000 claims description 4
229940024606 amino acid Drugs 0.000 claims description 3
230000001857 anti-mycotic effect Effects 0.000 claims description 3
239000002543 antimycotic Substances 0.000 claims description 3
239000000284 extract Substances 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
JJVXHDTWVIPRBZ-VKHMYHEASA-N (2r)-2-[carboxy(methyl)amino]-3-sulfanylpropanoic acid Chemical compound OC(=O)N(C)[C@@H](CS)C(O)=O JJVXHDTWVIPRBZ-VKHMYHEASA-N 0.000 claims description 2
244000098338 Triticum aestivum Species 0.000 claims description 2
230000001741 anti-phlogistic effect Effects 0.000 claims description 2
229960000333 benzydamine Drugs 0.000 claims description 2
239000003246 corticosteroid Substances 0.000 claims description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
229960001259 diclofenac Drugs 0.000 claims description 2
229960000890 hydrocortisone Drugs 0.000 claims description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
229960000991 ketoprofen Drugs 0.000 claims description 2
230000001569 mucosecretolytic effect Effects 0.000 claims description 2
150000003904 phospholipids Chemical class 0.000 claims description 2
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
229960002702 piroxicam Drugs 0.000 claims description 2
229920001983 poloxamer Polymers 0.000 claims description 2
150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
229960000230 sobrerol Drugs 0.000 claims description 2
OMDMTHRBGUBUCO-UHFFFAOYSA-N trans-sobrerol Natural products CC1=CCC(C(C)(C)O)CC1O OMDMTHRBGUBUCO-UHFFFAOYSA-N 0.000 claims description 2
230000029663 wound healing Effects 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims 8
HWIMWAMLHNOMRW-UHFFFAOYSA-N 3-(cyclopropylmethyl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC=NC=2N1CC1CC1 HWIMWAMLHNOMRW-UHFFFAOYSA-N 0.000 claims 1
229920000858 Cyclodextrin Polymers 0.000 claims 1
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229960001334 corticosteroids Drugs 0.000 claims 1
229940097362 cyclodextrins Drugs 0.000 claims 1
230000002519 immonomodulatory effect Effects 0.000 claims 1
229910052500 inorganic mineral Inorganic materials 0.000 claims 1
239000011707 mineral Substances 0.000 claims 1
239000002904 solvent Substances 0.000 abstract description 5
239000011877 solvent mixture Substances 0.000 abstract description 2
241000700159 Rattus Species 0.000 description 14
239000007864 aqueous solution Substances 0.000 description 13
239000000243 solution Substances 0.000 description 10
229940042130 topical foam Drugs 0.000 description 7
239000006264 topical foam Substances 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
235000010418 carrageenan Nutrition 0.000 description 5
229920001525 carrageenan Polymers 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000000202 analgesic effect Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 4
230000036407 pain Effects 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
229940044952 vaginal foam Drugs 0.000 description 4
239000000259 vaginal foam Substances 0.000 description 4
241000222122 Candida albicans Species 0.000 description 3
229940095731 candida albicans Drugs 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
229940042127 oral foam Drugs 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
206010046914 Vaginal infection Diseases 0.000 description 2
230000032683 aging Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
239000001282 iso-butane Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
KRCMKUNIILUXPF-UHFFFAOYSA-N methyl 4-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=C(O)C=C1 KRCMKUNIILUXPF-UHFFFAOYSA-N 0.000 description 2
229950004864 olamine Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 2
238000003892 spreading Methods 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
229960001312 tiaprofenic acid Drugs 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
231100000820 toxicity test Toxicity 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229960000281 trometamol Drugs 0.000 description 2
238000005303 weighing Methods 0.000 description 2
GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
WBQNUTJPYOXRCC-BTJKTKAUSA-N (z)-but-2-enedioic acid;n,2-dimethyl-4,5,6,7-tetrahydroindazol-3-amine Chemical compound OC(=O)\C=C/C(O)=O.C1CCCC2=NN(C)C(NC)=C21 WBQNUTJPYOXRCC-BTJKTKAUSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000206575 Chondrus crispus Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
239000006159 Sabouraud's agar Substances 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229950006137 dexfosfoserine Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
208000024386 fungal infectious disease Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
238000012009 microbiological test Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000012449 sabouraud dextrose agar Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000011493 spray foam Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
GUHPRPJDBZHYCJ-UHFFFAOYSA-N tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
229940100613 topical solution Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
-1 trimethylacetyl Chemical group 0.000 description 1
238000011121 vaginal smear Methods 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2066945 1991-04-24 1992-04-23 Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam Expired - Lifetime CA2066945C (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITMI91A001149		1991-04-24
ITMI911149A IT1247529B (it)	1991-04-24	1991-04-24	Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale

Publications (2)

Publication Number	Publication Date
CA2066945A1 CA2066945A1 (en)	1992-10-25
CA2066945C true CA2066945C (en)	2004-06-22

Family

ID=11359784

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2066945 Expired - Lifetime CA2066945C (en)	1991-04-24	1992-04-23	Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam

Country Status (5)

Country	Link
AT (1)	ATE140623T1 (cs)
CA (1)	CA2066945C (cs)
CZ (1)	CZ283238B6 (cs)
DE (2)	DE69212371T2 (cs)
RU (1)	RU2093146C1 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2289360C2 (ru) *	2004-05-26	2006-12-20	Государственное научное учреждение Северо-Кавказский зональный научно-исследовательский ветеринарный институт Российской академии сельскохозяйственных наук	Способ профилактики и лечения заболеваний полостных органов животных лекарственными веществами, вводимыми с пеной

1992
- 1992-04-21 DE DE1992612371 patent/DE69212371T2/de not_active Expired - Lifetime
- 1992-04-21 AT AT92106739T patent/ATE140623T1/de active
- 1992-04-21 DE DE1992106739 patent/DE510561T1/de active Pending
- 1992-04-23 CA CA 2066945 patent/CA2066945C/en not_active Expired - Lifetime
- 1992-04-23 CZ CS921239A patent/CZ283238B6/cs unknown
- 1992-04-23 RU SU5011762 patent/RU2093146C1/ru active

Also Published As

Publication number	Publication date
CZ283238B6 (cs)	1998-02-18
CS123992A3 (en)	1992-11-18
DE510561T1 (de)	1993-04-08
DE69212371T2 (de)	1997-01-16
RU2093146C1 (ru)	1997-10-20
DE69212371D1 (de)	1996-08-29
CA2066945A1 (en)	1992-10-25
ATE140623T1 (de)	1996-08-15

Legal Events

Date	Code	Title	Description
1999-08-18	EEER	Examination request
2012-04-23	MKEX	Expiry

Publication	Publication Date	Title
EP0510561B1 (en)	1996-07-24	Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
US6238683B1 (en)	2001-05-29	Anhydrous topical skin preparations
US8735393B2 (en)	2014-05-27	Anhydrous topical skin preparations
ES2599973T3 (es)	2017-02-06	Una formulación tópica de propionato de clobetasol de nivel bajo para tratar trastornos de la membrana mucosa y de la piel
CA2683217A1 (en)	2008-10-09	Compositions for nasal delivery
NO311919B1 (no)	2002-02-18	Transdermalt medikament
AU2006326388A1 (en)	2007-06-21	Compositions and methods for treating dermatological conditions
JPH09176013A (ja)	1997-07-08	急性鼻炎を処置するための医薬製剤
RU2397769C2 (ru)	2010-08-27	Применение состава для распыления, содержащего клобетазол, для лечения псориаза
CA2066945C (en)	2004-06-22	Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
JP4450545B2 (ja)	2010-04-14	エアゾール製剤
WO2019161470A1 (pt)	2019-08-29	Composição farmacêutica na forma de suspensão aquosa e uso de uma composição farmacêutica na forma de suspensão aquosa
ES2296209T5 (es)	2011-04-19	Composición en forma de un spray que comprende una combinación de propionato de clobetasol y calcitriol, una fase alcohólica y una fase oleosa.
JPH02193932A (ja)	1990-07-31	経皮、経粘膜吸収促進剤および経皮、経粘膜製剤
US20120238535A1 (en)	2012-09-20	Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes
WO2002102385A1 (en)	2002-12-27	Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
SE2151519A1 (en)	2023-06-11	2-(2,5-dimethoxyphenyl)ethanamine and uses thereof
ES2289897B1 (es)	2008-12-16	Composicion para administracion transdermica de agentes fisiologicamente activos.
ES2341784T3 (es)	2010-06-28	Composicion farmaceutica que contiene en asociacion ubidecarenona, dexpantenol y clorhexidina o una sal farmaceuticamente aceptable de los mismos para aplicacion cutanea.
AU2022236886A1 (en)	2023-11-02	Methods of using compositions comprising an iceland moss extract
JPH10182497A (ja)	1998-07-07	外用組成物
EP1159956A2 (en)	2001-12-05	Anhydrous topical skin preparations
JP2004196738A (ja)	2004-07-15	炎症性疾患治療薬としての局所用医薬品組成物
MXPA00007720A (en)	2002-05-09	Anhydrous topical skin preparations
JPH10182427A (ja)	1998-07-07	外用組成物